Search - tctmd.com

Displaying 301 - 320 of 852

Sort: Relevancy | Date

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Daily News

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

Michael O'Riordan

August 18, 2022

News Daily News

CV Symptoms Deserve More Attention, Quantification: AHA Statement

Yael L. Maxwell

August 18, 2022

News Daily News

‘Stunning’ Lack of Data on CV Issues in Pregnant Women With COVID-19

L.A. McKeown

August 10, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for July 2022

Todd Neale

August 01, 2022

News Daily News

Early LV Recovery After TAVI Points to Better 5-Year Survival

Yael L. Maxwell

August 01, 2022

News Daily News

LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD

Michael O'Riordan

July 11, 2022

News Features

A Hole in the Heart for HFpEF? Setbacks, Progress for Interatrial Shunts

Shelley Wood

July 07, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for June 2022

Caitlin E. Cox

July 04, 2022

News Opinion Off Script

To Save a Dying Mother

Kathryn J. Lindley, MD

June 28, 2022

News Daily News

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

L.A. McKeown

June 21, 2022

News Features

Climate Cardiology: If Not Now, When?

Caitlin E. Cox

June 20, 2022

News Daily News

Multidisciplinary Collaboration Tackles CV-Related Long COVID

Todd Neale

June 14, 2022

News Daily News

Heart Failure Risks of Smoking Can Linger for Decades

L.A. McKeown

June 07, 2022

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for May 2022

Shelley Wood

June 01, 2022

News Conference News ESC Heart Failure 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

Todd Neale

May 31, 2022

News Conference News ESC Heart Failure 2022

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

Shelley Wood

May 25, 2022

News Conference News ESC Heart Failure 2022

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

Shelley Wood

May 23, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Conference News ESC Heart Failure 2022

Speech-Recognition Tool May Predict Worsening Congestion in HF

Shelley Wood

May 22, 2022

Advertisement

What’s Going to Be Hot at ESC 2022?

AHA Urges More Home-Based Dialysis in Advanced Kidney Failure

CV Symptoms Deserve More Attention, Quantification: AHA Statement

‘Stunning’ Lack of Data on CV Issues in Pregnant Women With COVID-19

TCTMD’s Top 10 Most Popular Stories for July 2022

Early LV Recovery After TAVI Points to Better 5-Year Survival

LVEF Analysis Digs Anew Into Revascularization Benefits in Ischemic CAD

A Hole in the Heart for HFpEF? Setbacks, Progress for Interatrial Shunts

TCTMD’s Top 10 Most Popular Stories for June 2022

To Save a Dying Mother

Quadruple Therapy Costs Prohibitive for Many HFrEF Patients

Climate Cardiology: If Not Now, When?

Multidisciplinary Collaboration Tackles CV-Related Long COVID

Heart Failure Risks of Smoking Can Linger for Decades

TCTMD’s Top 10 Most Popular Stories for May 2022

Aficamten Safe, Effective for Up to 6 Months in Obstructive HCM: REDWOOD-HCM OLE

HF Triple Therapy Doesn’t Seem Effective in True Preserved HF

Sweet Spot for Omecamtiv Mecarbil in HFrEF May Lie in Low SBP Patients

Dapagliflozin Boosts Health Status Across LVEF Range

Speech-Recognition Tool May Predict Worsening Congestion in HF

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content